Unravelling neurotransmitters impairment in primary progressive aphasias

Primary progressive aphasias (PPAs) are a group of neurodegenerative diseases mainly characterized by language impairment, and with variably presence of dysexecutive syndrome, behavioural disturbances and parkinsonism. Detailed knowledge of neurotransmitters impairment and its association with clinical features hold the potential to develop new tailored therapeutic approaches. In the present study, we applied JuSpace toolbox, which allowed for cross‐modal correlation of magnetic resonance imaging (MRI)‐based measures with nuclear imaging derived estimates covering various neurotransmitter systems including dopaminergic, serotonergic, noradrenergic, GABAergic and glutamatergic neurotransmission. We included 103 PPA patients and 80 age‐matched healthy controls (HC). We tested if the spatial patterns of grey matter volume (GMV) alterations in PPA patients (relative to HC) are correlated with specific neurotransmitter systems. As compared to HC, voxel‐based brain changes in PPA were significantly associated with spatial distribution of serotonin, dopamine, and glutamatergic pathways (p < .05, False Discovery Rate corrected‐corrected). Disease severity was negatively correlated with the strength of GMV colocalization of D1 receptors (p = .035) and serotonin transporter (p = .020). Moreover, we observed a significant negative correlation between positive behavioural symptoms, as measured with Frontal Behavioural Inventory, and GMV colocalization of D1 receptors (p = .007) and serotonin transporter (p < .001). This pilot study suggests that JuSpace is a helpful tool to indirectly assess neurotransmitter deficits in neurodegenerative dementias and may provide novel insight into disease mechanisms and associated clinical features.

[1]  C. Lüscher,et al.  Synaptic mechanism underlying serotonin modulation of transition to cocaine addiction , 2021, Science.

[2]  R. Laforce,et al.  Longitudinal Changes in Cognition, Behaviours, and Functional Abilities in the Three Main Variants of Primary Progressive Aphasia: A Literature Review , 2021, Brain sciences.

[3]  M. Cotelli,et al.  Language training for oral and written naming impairment in primary progressive aphasia: a review , 2021, Translational neurodegeneration.

[4]  G. Knudsen,et al.  The Modulatory Role of Serotonin on Human Impulsive Aggression , 2021, Biological Psychiatry.

[5]  M. Yus,et al.  Personalized Repetitive Transcranial Magnetic Stimulation for Primary Progressive Aphasia. , 2021, Journal of Alzheimer's disease : JAD.

[6]  Peter C. T. Hawkins,et al.  JuSpace: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps , 2020, bioRxiv.

[7]  F. Panza,et al.  Development of disease-modifying drugs for frontotemporal dementia spectrum disorders , 2020, Nature Reviews Neurology.

[8]  V. Di Lazzaro,et al.  Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias , 2020, Annals of neurology.

[9]  David T. Jones,et al.  Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[10]  R. Manenti,et al.  Transcranial stimulation in frontotemporal dementia: A randomized, double‐blind, sham‐controlled trial , 2020, Alzheimer's & dementia.

[11]  B. Borroni,et al.  TMS for staging and predicting functional decline in frontotemporal dementia , 2019, Brain Stimulation.

[12]  M. Gorno-Tempini,et al.  Primary progressive aphasia: a model for neurodegenerative disease , 2019, Current opinion in neurology.

[13]  J. Desmond,et al.  Electrical brain stimulation in different variants of primary progressive aphasia: A randomized clinical trial , 2018, Alzheimer's & dementia.

[14]  Nick C Fox,et al.  Primary progressive aphasia: a clinical approach , 2018, Journal of Neurology.

[15]  J. Rowe,et al.  Neurotransmitter deficits from frontotemporal lobar degeneration , 2018, Brain : a journal of neurology.

[16]  V. Voon,et al.  Serotonin transporter density in binge eating disorder and pathological gambling: A PET study with [11C]MADAM , 2017, European Neuropsychopharmacology.

[17]  Christopher H. Chatham,et al.  Cerebral blood flow predicts differential neurotransmitter activity , 2017, bioRxiv.

[18]  Hiroshi Matsuda,et al.  Comparing CAT12 and VBM8 for Detecting Brain Morphological Abnormalities in Temporal Lobe Epilepsy , 2017, Front. Neurol..

[19]  Alessandra Flammini,et al.  Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia , 2017, Neurology.

[20]  E. Gómez-Tortosa,et al.  Behavioral Evolution of Progressive Semantic Aphasia in Comparison with Nonfluent Aphasia , 2015, Dementia and Geriatric Cognitive Disorders.

[21]  J. Duffy,et al.  Neuropsychological Profiles Differ among the Three Variants of Primary Progressive Aphasia , 2015, Journal of the International Neuropsychological Society.

[22]  Eileen Luders,et al.  A 12-step user guide for analyzing voxel-wise gray matter asymmetries in statistical parametric mapping (SPM) , 2015, Nature Protocols.

[23]  Franco Cauda,et al.  Multimodal fMRI Resting-State Functional Connectivity in Granulin Mutations: The Case of Fronto-Parietal Dementia , 2014, PloS one.

[24]  R. Petersen,et al.  Neuropsychiatric aspects of primary progressive aphasia. , 2011, The Journal of neuropsychiatry and clinical neurosciences.

[25]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[26]  D. Gitelman,et al.  Pilot trial of memantine in primary progressive aphasia. , 2010, Alzheimer disease and associated disorders.

[27]  M. Luca,et al.  Establishing short-term prognosis in Frontotemporal Lobar Degeneration spectrum: Role of genetic background and clinical phenotype , 2010, Neurobiology of Aging.

[28]  S. Weintraub,et al.  Generalized and symptom-specific insight in behavioral variant frontotemporal dementia and primary progressive aphasia. , 2009, The Journal of neuropsychiatry and clinical neurosciences.

[29]  A. Kertesz,et al.  Galantamine in Frontotemporal Dementia and Primary Progressive Aphasia , 2008, Dementia and Geriatric Cognitive Disorders.

[30]  B L Miller,et al.  Behavioral features in semantic dementia vs other forms of progressive aphasias , 2006, Neurology.

[31]  A. Kertesz,et al.  The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia , 2000, Neurology.

[32]  Mark D'Esposito,et al.  Progressive Nonfluent Aphasia: Language, Cognitive, and PET Measures Contrasted with Probable Alzheimer's Disease , 1996, Journal of Cognitive Neuroscience.

[33]  J. Hodges,et al.  Comparing Longitudinal Behavior Changes in the Primary Progressive Aphasias. , 2016, Journal of Alzheimer's disease : JAD.

[34]  B. Borroni,et al.  Looking for Measures of Disease Severity in the Frontotemporal Dementia Continuum. , 2016, Journal of Alzheimer's disease : JAD.

[35]  C. Miniussi,et al.  Treatment of primary progressive aphasias by transcranial direct current stimulation combined with language training. , 2014, Journal of Alzheimer's disease : JAD.